N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl) benzyl)-1-methyl-1h-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: In vivo profiling suggests a link between behavioral and central nervous system neurochemical changes

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 165-177

  Fell, Matthew J ^a   Witkin, Jeffrey M ^a   Falcone, Julie F ^a   Katner, Jason S ^a   Perry, Kenneth W ^a   Hart, John ^a   Rorick Kehn, Linda ^a   Overshiner, Carl D ^a   Rasmussen, Kurt ^a   Chaney, Stephen F ^a   Benvenga, Mark J ^a   Li, Xia ^a   Marlow, Deanna L ^a   Thompson, Linda K ^a   Luecke, Susan K ^a   Wafford, Keith A ^a   Seidel, Wesley F ^a   Edgar, Dale M ^a   Quets, Anne T ^a   Felder, Christian C ^a   Wang, Xu Shan ^a   Heinz, Beverly A ^a   Nikolayev, Alexander ^a   Kuo, Ming Shang ^a   Mayhugh, Daniel ^a   Khilevich, Albert ^a   Zhang, Deyi ^a   Ebert, Philip J ^a   Eckstein, James A ^a   Ackermann, Bradley L ^a   Swanson, Steven P ^a   Catlow, John T ^a   Dean, Robert A ^a   Jackson, Kimberley ^a   Tauscher Wisniewski, Sitra ^a   Marek, Gerard J ^a   Schkeryantz, Jeffrey M ^a   Svensson, Kjell A ^a   more..

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HISTAMINE; IMIPRAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; N [4 [[2 (TRIFLUOROMETHYL) 3 HYDROXY 4 (ISOBUTYRYL)PHENOXY]METHYL]BENZYL] 1 METHYL 1H IMIDAZOLE 4 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; DRUG EFFICACY; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; GENOTYPE; HYPERTHERMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REM SLEEP; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZYL COMPOUNDS; CELL LINE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; DRUG SYNERGISM; EXCITATORY AMINO ACID AGONISTS; HUMANS; IMIDAZOLES; MALE; MICE; MICE, KNOCKOUT; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 78650769933     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.172957     Document Type: Article

References (40)

1. Ahnaou A, Dautzenberg FM, Geys H, Imogai H, Gibelin A, Moechars D, Steckler T, and Drinkenburg WH (2009) Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol 603:62-72.
2. Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, and Nicoletti F (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013-1033.
3. Cartmell J, Perry KW, Salhoff CR, Monn JA, and Schoepp DD (2001) Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 40:847-855.
4. Chalon S, Pereira A, Lainey E, Vandenhende F, Watkin JG, Staner L, and Granier LA (2005) Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology 177:357-365.
5. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
6. Di Giorgi-Gerevini V, Melchiorri D, Battaglia G, Ricci-Vitiani L, Ciceroni C, Busceti CL, Biagioni F, Iacovelli L, Canudas AM, Parati E, et al. (2005) Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells. Cell Death Differ 12:1124-1133. (Pubitemid 41065429)
7. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, and Tollefson GD (2008) Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33:1603-1610. (Pubitemid 351684700)
8. Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, and Berger M (2002) Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 26:246-258.
9. Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, and Svensson KA (2010) Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. Neuropharmacology 58:632-639.
10. Fell MJ, Svensson KA, Johnson BG, and Schoepp DD (2008) Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1. 0]hexane- 4,6-dicarboxylic acidLY404039. J Pharmacol Exp Ther 326:209-217.
11. Frisch C, Hasenöhrl RU, Krauth J, and Huston JP (1998) Anxiolytic-like behavior after lesion of the tuberomammillary nucleus E2-region. Exp Brain Res 119:260-264.
12. Galici R, Echemendia NG, Rodriguez AL, and Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181-1187.
13. Grillon C, Cordova J, Levine LR, and Morgan CA 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fearpotentiated startle paradigm in humans. Psychopharmacology 168:446-454.
14. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271-283.
15. Khilevich A, Liu B, Mayhugh DR, Schkeryantz JM, and Zhang D (2008) inventors; Eli Lilly and Company, assignee. Imidazole carboxamides. International patent application WO2010009062. 2008 July 18.
16. Li X, Morrow D, and Witkin JM (2006) Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78:1933-1939.
17. Marek GJ, Li AA, and Seiden LS (1989) Evidence for involvement of 5-hydroxytryptamine1 receptors in antidepressant-like drug effects on differential-reinforcement-of-low-rate 72-second behavior. J Pharmacol Exp Ther 250:60-71.
18. Marek GJ, Martin-Ruiz R, Abo A, and Artigas F (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30:2205-2215.
19. Matrisciano F, Zusso M, Panaccione I, Turriziani B, Caruso A, Iacovelli L, Noviello L, Togna G, Melchiorri D, Debetto P, et al. (2008) Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis. Neuropharmacology 54:428-437.
20. Mayers AG and Baldwin DS (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol 20:533-559.
21. Oishi R, Itoh Y, and Saeki K (1992) Inhibition of histamine turnover by 8-OH-DPAT, buspirone and 5-hydroxytryptophan in the mouse and rat brain. Naunyn Schmiedebergs Arch Pharmacol 345:495-499.
22. Oishi R, Nishibori M, Itoh Y, and Saeki K (1986) Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol 124:337-342. (Pubitemid 16090474)
23. Okakura K, Yamatodani A, Mochizuki T, Horii A, and Wada H (1992) Glutamatergic regulation of histamine release from rat hypothalamus. Eur J Pharmacol 213: 189-192.
24. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107.
25. Porsolt RD, Bertin A, and Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
26. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, et al. (2007a) Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: In vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6- dicarboxylic acid (LY404039). J Pharmacol Exp Ther 321:308-317.
27. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, et al. (2007b) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193:121-136.
28. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, and McKinzie DL (2006) Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 316:905-913.
29. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12-20.
30. Schoepp DD and Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1:215-225.
31. Schoepp DD, Wright RA, Levine LR, Gaydos B, and Potter WZ (2003) LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6:189-197.
32. Soya A, Song YH, Kodama T, Honda Y, Fujiki N, and Nishino S (2008) CSF histamine levels in rats reflect the central histamine neurotransmission. Neurosci Lett 430:224-229.
33. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, and Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-170.
34. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
35. Thase ME (2006) Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 8:217-226.
36. Witkin JM and Eiler WJA II (2006) Antagonism of metabotropic glutamate group II receptors in the potential treatment of neurological and neuropsychiatric disorders. Drug Dev Res 67:757-769.
37. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103:1-20.
38. Witkin JM, Marek GJ, Johnson BG, and Schoepp DD (2007) Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 6:87-100.
39. Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, and Schoepp DD (2001) [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 298:453-460.
40. Zarrindast MR, Moghadam AH, Rostami P, and Roohbakhsh A (2005) The effects of histaminergic agents in the central amygdala of rats in the elevated plus-maze test of anxiety. Behav Pharmacol 16:643-649. (Pubitemid 41682199)